News >

Clinical Trials Exploring Novel Options for T-Cell Lymphoma

Gina Columbus @ginacolumbusonc
Published: Wednesday, Jun 28, 2017

Jia Ruan, MD, PhD

Jia Ruan, MD, PhD

Long-term outcomes for T-cell lymphoma remain suboptimal, explains Jia Ruan, MD, PhD. However, ongoing studies are investigating exciting regimens—including additions to the standard CHOP regimen—that could have the potential to change practice for these patients.

on Hematologic Malignancies.

OncLive: What did you discuss in your lecture on T-cell lymphoma?

Ruan: I see a lot of patients in our group for non-Hodgkin lymphoma (NHL) and there is 1 distinct subtype, which is T-cell lymphoma. It is not a very common subtype, it is in about 5% to 20% of patients with NHL. But, it is quite heterogeneous and also very difficult to treat. The long-term outcomes for patients with T-cell lymphoma remain suboptimal. For example, the studies generally state that it is a 5-year survival rate of about 20% to 30%, which certainly has room for improvement. 

Subsequent to that, patients could have options to move on to consolidative bone marrow transplant or they can consider maintenance strategies in order to remain in remission longer. 

How does T-cell lymphoma present, and what are the characteristics of it?

Peripheral T-cell lymphoma, the most common subtype, includes angioimmunoblastic T-cell lymphoma or anaplastic large cell lymphoma. Patients with those diseases can present with very symptomatic lymphadenopathy, which is swelling of lymph nodes. They may have some fevers, constitutional symptoms like weight loss, and also a significant proportion of those patients may have skin rash and inflammatory symptoms.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication